Key poster presentations include:
Poster 90: “Effects of Aripiprazole Lauroxil on Agitation and Hostility
in Patients with Schizophrenia” will be presented by
Poster 142: “A Phase 2, Randomized, Olanzapine-Controlled Study of the
Safety, Tolerability and Efficacy of ALKS 3831 in Adults with
Schizophrenia” will be presented by
Poster 145: “Effect of Aripiprazole Lauroxil on Metabolic and Endocrine
Profiles, and Related Safety Considerations in Acute Schizophrenia” will
be presented by
Poster 146: “Efficacy and Safety of Aripiprazole Lauroxil in Patients
Experiencing Severe Psychotic Symptoms During an Acute Exacerbation of
Schizophrenia” will be presented by
Poster 147: “Effect of Aripiprazole Lauroxil on Personal and Social
Functioning and Health-Related Quality of Life Among Patients with
Schizophrenia” will be presented by
A full list of all
About Aripiprazole Lauroxil
Aripiprazole lauroxil is an injectable atypical antipsychotic with one-month and extended-duration formulations in development for the treatment of schizophrenia. Once in the body, aripiprazole lauroxil converts to aripiprazole, which is commercially available under the name ABILIFY®. As a long-acting investigational medication based on Alkermes’ proprietary LinkeRx® technology, aripiprazole lauroxil is designed to have multiple dosing options and to be administered in a ready-to-use, pre-filled product format.
About ALKS 3831
ALKS 3831 is a proprietary, investigational medicine designed as a broad-spectrum antipsychotic for the treatment of schizophrenia. ALKS 3831 is composed of samidorphan, a novel, potent mu-opioid antagonist, in combination with the established antipsychotic drug, olanzapine. ALKS 3831 is designed to attenuate olanzapine-induced metabolic side effects, including weight gain, in patients with schizophrenia and to have utility in the treatment of schizophrenia in patients with alcohol use.
About Alkermes
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including, but not
limited to, statements concerning the therapeutic value of aripiprazole
lauroxil and ALKS 3831. You are cautioned that forward-looking
statements are inherently uncertain. Although the company believes that
such statements are based on reasonable assumptions within the bounds of
its knowledge of its business and operations, the forward-looking
statements are neither promises nor guarantees and are subject to a
variety of risks and uncertainties, many of which are beyond the
company’s control, which could cause actual results to differ materially
from those expressed or implied in the forward-looking statements. These
risks and uncertainties include, among others, whether preclinical and
clinical results for ALKS 3831 will be predictive of future clinical
study results; whether ALKS 3831 or aripiprazole lauroxil could be shown
to be unsafe or ineffective; and those risks described in the
LinkeRx® is a registered trademark of
Source:
Alkermes Contacts:
For Investors:
Rebecca
Peterson, +1 781-609-6378
or
For Media:
Jennifer Snyder,
+1 781-609-6166